• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Comparative Study of Efficacy and Safety of Gabapentin and Amitriptyline in Treatment of Neuropathic Pain Associated with Chronic Lumbar Radiculopathy. An Open Label, Prospective Randomized Clinical Study.

    Dr Shaikh Huzaif, Dr Syed Maaz Hussain , Dr Shadab Munawar Moosa, Dr Imran Nawaz Khan, Dr Afshan Kausar, Dr Quazi Zubair

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 5024-5031

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Title: Comparative study of efficacy and safety of gabapentin and amitriptyline in treatment of neuropathic pain associated with chronic lumbar radiculopathy. An open label, prospective randomized clinical study.
Background: Chronic lumbar radiculopathy is a clinical condition characterized by back and leg pain associated with sensory, reflex, or motor deficits in the area of nerve root distribution lasting for more than 12 weeks. The lifetime prevalence of lumbar radiculopathy has been reported to be 5.3% in men and 3.7% in women.
Objective: To evaluate the efficacy and safety of gabapentin and amitriptyline in patients with chronic lumbar radiculopathy by measuring the change in NPRS score.
Material and Methods: The present study was conducted in the outpatient department (OPD) of orthopedics in collaboration with department of pharmacology. It was a 12 weeks randomized comparative open label single centre two arm prospective study. Total patients were randomized equally into 2 groups. Patients in Group ‘A’ received Tablet Gabapentin 300 mg two times in a day and Patients in Group ‘B’ received Tablet Amitriptyline 10 mg. Pain intensity was assessed at baseline (0 week), at 6 weeks and at 12 weeks of starting the treatment using Numeric pain rating scale (NPRS).
Keywords:
  • PDF (308 K)
  • XML
(2022). Comparative Study of Efficacy and Safety of Gabapentin and Amitriptyline in Treatment of Neuropathic Pain Associated with Chronic Lumbar Radiculopathy. An Open Label, Prospective Randomized Clinical Study.. European Journal of Molecular & Clinical Medicine, 9(3), 5024-5031.
Dr Shaikh Huzaif, Dr Syed Maaz Hussain , Dr Shadab Munawar Moosa, Dr Imran Nawaz Khan, Dr Afshan Kausar, Dr Quazi Zubair. "Comparative Study of Efficacy and Safety of Gabapentin and Amitriptyline in Treatment of Neuropathic Pain Associated with Chronic Lumbar Radiculopathy. An Open Label, Prospective Randomized Clinical Study.". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 5024-5031.
(2022). 'Comparative Study of Efficacy and Safety of Gabapentin and Amitriptyline in Treatment of Neuropathic Pain Associated with Chronic Lumbar Radiculopathy. An Open Label, Prospective Randomized Clinical Study.', European Journal of Molecular & Clinical Medicine, 9(3), pp. 5024-5031.
Comparative Study of Efficacy and Safety of Gabapentin and Amitriptyline in Treatment of Neuropathic Pain Associated with Chronic Lumbar Radiculopathy. An Open Label, Prospective Randomized Clinical Study.. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 5024-5031.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 194
  • PDF Download: 244
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus